Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free ACB Stock Alerts

Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
C$5.37 -0.20 (-3.59%)
As of 09/3/2026 04:00 PM Eastern
Compare

ACB vs. DB, DHT.UN, THCX, GUD, and TLRY

Should you buy Aurora Cannabis stock or one of its competitors? Aurora Cannabis's main competitors and comparable companies include Decibel Cannabis (DB), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Knight Therapeutics (GUD), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aurora Cannabis compare to Decibel Cannabis?

Aurora Cannabis (TSE:ACB) and Decibel Cannabis (CVE:DB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Aurora Cannabis currently has a consensus target price of C$6.20, suggesting a potential upside of 15.46%. Decibel Cannabis has a consensus target price of C$0.18, suggesting a potential downside of 90.33%. Given Aurora Cannabis' higher probable upside, equities analysts plainly believe Aurora Cannabis is more favorable than Decibel Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Decibel Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

In the previous week, Aurora Cannabis had 4 more articles in the media than Decibel Cannabis. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Decibel Cannabis. Decibel Cannabis' average media sentiment score of 0.00 beat Aurora Cannabis' score of -1.09 indicating that Decibel Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Negative
Decibel Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Decibel Cannabis has a net margin of -3.78% compared to Aurora Cannabis' net margin of -9.53%. Decibel Cannabis' return on equity of -1.05% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
Decibel Cannabis -3.78%-1.05%3.04%

Aurora Cannabis has a beta of 0.246838, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Decibel Cannabis has a beta of 0.321627, suggesting that its share price is 68% less volatile than the broader market.

Decibel Cannabis has lower revenue, but higher earnings than Aurora Cannabis. Decibel Cannabis is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.06-C$44.16M-C$1.94N/A
Decibel CannabisC$127.08M0.55-C$1.03M-C$0.15N/A

4.1% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 0.0% of Decibel Cannabis shares are owned by institutional investors. 1.1% of Decibel Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Decibel Cannabis beats Aurora Cannabis on 10 of the 17 factors compared between the two stocks.

How does Aurora Cannabis compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

DRI Healthcare Trust has a net margin of 5.02% compared to Aurora Cannabis' net margin of -9.53%. DRI Healthcare Trust's return on equity of 2.06% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
DRI Healthcare Trust5.02% 2.06% 4.22%
Aurora Cannabis -9.53%-5.21%-1.87%

DRI Healthcare Trust currently has a consensus price target of C$25.20, suggesting a potential upside of 44.33%. Aurora Cannabis has a consensus price target of C$6.20, suggesting a potential upside of 15.46%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts clearly believe DRI Healthcare Trust is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

DRI Healthcare Trust has higher earnings, but lower revenue than Aurora Cannabis. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DRI Healthcare TrustC$172.34M5.57C$9.73M-C$0.80N/A
Aurora CannabisC$314.07M1.06-C$44.16M-C$1.94N/A

0.8% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 4.1% of Aurora Cannabis shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DRI Healthcare Trust has a beta of 0.365327, indicating that its share price is 63% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.246838, indicating that its share price is 75% less volatile than the broader market.

In the previous week, Aurora Cannabis had 3 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 5 mentions for Aurora Cannabis and 2 mentions for DRI Healthcare Trust. DRI Healthcare Trust's average media sentiment score of 1.49 beat Aurora Cannabis' score of -1.09 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DRI Healthcare Trust
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Negative

Summary

DRI Healthcare Trust beats Aurora Cannabis on 13 of the 17 factors compared between the two stocks.

How does Aurora Cannabis compare to Hydropothecary?

Aurora Cannabis (TSE:ACB) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Aurora Cannabis had 5 more articles in the media than Hydropothecary. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for Hydropothecary. Hydropothecary's average media sentiment score of 0.00 beat Aurora Cannabis' score of -1.09 indicating that Hydropothecary is being referred to more favorably in the news media.

Company Overall Sentiment
Aurora Cannabis Negative
Hydropothecary Neutral

4.1% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hydropothecary has lower revenue, but higher earnings than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.06-C$44.16M-C$1.94N/A
HydropothecaryN/AN/AN/AN/AN/A

Hydropothecary has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. Hydropothecary's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
Hydropothecary N/A N/A N/A

Aurora Cannabis presently has a consensus target price of C$6.20, suggesting a potential upside of 15.46%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, research analysts plainly believe Aurora Cannabis is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aurora Cannabis beats Hydropothecary on 6 of the 10 factors compared between the two stocks.

How does Aurora Cannabis compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Knight Therapeutics has a beta of -0.290935, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.246838, suggesting that its stock price is 75% less volatile than the broader market.

Knight Therapeutics currently has a consensus price target of C$9.50, suggesting a potential downside of 5.38%. Aurora Cannabis has a consensus price target of C$6.20, suggesting a potential upside of 15.46%. Given Aurora Cannabis' higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Knight Therapeutics has a net margin of 2.72% compared to Aurora Cannabis' net margin of -9.53%. Knight Therapeutics' return on equity of 1.91% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
Aurora Cannabis -9.53%-5.21%-1.87%

22.7% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Aurora Cannabis shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Knight Therapeutics has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.80-C$30.73MC$0.1566.93
Aurora CannabisC$314.07M1.06-C$44.16M-C$1.94N/A

In the previous week, Aurora Cannabis had 4 more articles in the media than Knight Therapeutics. MarketBeat recorded 5 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.95 beat Aurora Cannabis' score of -1.09 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Knight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Negative

Summary

Knight Therapeutics beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Aurora Cannabis has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$915.45M0.94-C$183.24M-C$1.09N/A
Aurora CannabisC$314.07M1.06-C$44.16M-C$1.94N/A

Tilray Brands has a beta of 3.215277, suggesting that its stock price is 222% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.246838, suggesting that its stock price is 75% less volatile than the broader market.

4.2% of Tilray Brands shares are held by institutional investors. Comparatively, 4.1% of Aurora Cannabis shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tilray Brands presently has a consensus target price of C$13.30, suggesting a potential upside of 113.48%. Aurora Cannabis has a consensus target price of C$6.20, suggesting a potential upside of 15.46%. Given Tilray Brands' higher possible upside, equities analysts plainly believe Tilray Brands is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Aurora Cannabis had 5 more articles in the media than Tilray Brands. MarketBeat recorded 5 mentions for Aurora Cannabis and 0 mentions for Tilray Brands. Tilray Brands' average media sentiment score of 0.71 beat Aurora Cannabis' score of -1.09 indicating that Tilray Brands is being referred to more favorably in the media.

Company Overall Sentiment
Tilray Brands Positive
Aurora Cannabis Negative

Aurora Cannabis has a net margin of -9.53% compared to Tilray Brands' net margin of -15.22%. Aurora Cannabis' return on equity of -5.21% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-15.22% -8.85% -1.41%
Aurora Cannabis -9.53%-5.21%-1.87%

Summary

Tilray Brands and Aurora Cannabis tied by winning 8 of the 16 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

Export
MetricAurora CannabisPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$332.71MC$12.25BC$7.26BC$12.57B
Dividend YieldN/A2.59%2.53%6.25%
P/E Ratio-2.77787.27273.2939.47
Price / Sales1.06753.78613.459.82
Price / Cash1.2594.8077.8282.29
Price / Book0.6312.3312.894.71
Net Income-C$44.16MC$2.82BC$3.47BC$299.09M
7 Day Performance-3.59%2.59%0.60%-0.31%
1 Month Performance37.34%6.95%5.73%3.12%
1 Year Performance-19.73%9.45%25.35%28.73%

Aurora Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
1.5262 of 5 stars		C$5.37
-3.6%		C$6.20
+15.5%		-20.7%C$332.71MC$314.07MN/A1,073
DB
Decibel Cannabis
0.7723 of 5 stars		C$1.93
+2.9%		C$0.18
-90.9%		+1,292.3%C$1.11BC$127.08MN/A83,000
DHT.UN
DRI Healthcare Trust
2.7232 of 5 stars		C$17.81
+2.1%		C$25.20
+41.5%		+19.8%C$978.89MC$172.34MN/AN/A
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
GUD
Knight Therapeutics
0.994 of 5 stars		C$9.64
-0.2%		C$9.50
-1.5%		+55.2%C$946.96MC$547.31M64.27725

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:ACB) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel